Third generation test tube PGT-A technology: How to scientifically improve the success rate of test tube babies

What is PGT-A? Why is it always called the key technology to improve the success rate of IVF?

PGT-A stands for Preimplantation Genetic Testing for Aneuploidies, that isPreimplantation Aneuploidy Testing. It is the core component of the third-generation in vitro fertilization technology (PGD/PGS). Before embryo transfer, blastocysts are screened for chromosomes to select embryos with normal chromosome numbers (euploid) for transplantation.

Normal human somatic cells have 46 chromosomes (23 pairs), and aneuploidy refers to one or more chromosomes that are one or several more or less, which is the main cause of embryo implantation failure, miscarriage or congenital defects. Research data shows that about 50% of early miscarriages are related to embryonic chromosomal abnormalities.

How PGT-A works

The testing process of PGT-A is as follows:

1. in vitro fertilization: Eggs are obtained through egg retrieval surgery and fertilized with sperm in the laboratory to form fertilized eggs.
2. embryo culture: The fertilized egg is cultured in an incubator for 5-6 days to form a blastocyst.
3. biopsy sampling: Take 5-10 cells from the outer trophoblast (placental origin) of the blastocyst under a microscope
4. genetic testing: Perform NGS (Next Generation Sequencing) or chip detection on biopsy cells to analyze the number of chromosomes
5. Result analysis: Screening out embryos with normal chromosomes for transplantation

Who is more suitable for incorporating PGT-A into an IVF regimen?

• history of recurrent miscarriage: Women who have experienced 2 or more spontaneous abortions
• Repeated transplant failure: Patients who have experienced more than 3 unsuccessful embryo transfers
• advanced maternal age: For women over 35 years old, the risk of chromosomal abnormalities increases significantly with age.
• balanced chromosome translocation carriers: One spouse has a chromosomal structural abnormality
• Hope for good health and good education: Couples who want to reduce the risk of chromosomal abnormalities through technological means

Core Values ​​of PGT-A: Why Does It Affect Transplantation Efficiency and Miscarriage Risk?

1. Significantly reduce miscarriage rate

According to international mainstream reproductive medicine research data, PGT-A can reduce the rate of spontaneous abortion by 30-50%. This is because embryos with chromosomal abnormalities are screened out and early miscarriage caused by defects in the embryo itself is avoided.

2. Improve the success rate of single transplantation

The clinical pregnancy rate of traditional IVF is about 40-50%, while the embryo transfer success rate after PGT-A screening can be increased to 60-70%. For younger patients (<35 years), the success rate is higher.

3. Reduce the risk of multiple pregnancy

Screening the best quality single embryo for transplantation through PGT-A can significantly reduce the risk of premature birth and low birth weight complications caused by multiple pregnancies (twins/triples) and achieveSingle embryo transfer (SET)security goals.

4. Shorten the time to prepare for pregnancy

Traditional programs often require multiple transplant failures to detect problems, but PGT-A screens before the first transplant, avoiding unnecessary time and economic losses.

Limitations and misunderstandings of PGT-A: What can it and cannot do?

No technology is perfect, and PGT-A also has the following limitations:

• Biopsy risks: Although the technology is mature, the sampling process may still cause slight damage to the embryos (approximately <1%)
• chimera problem: About 5% of blastocysts have mosaic chromosomes (some cells are normal and some are abnormal), and the test results may not fully represent the whole
• Testing fee: PGT-A testing costs approximately US$3,000-8,000, which increases the overall cost of treatment.
• Unable to detect single gene diseases: PGT-A only screens the number of chromosomes and cannot replace PGT-M (single gene disease testing)

Practical application of PGT-A in overseas assisted reproduction and surrogacy

In recent years, more and more Chinese families have chosen to go overseas for third-generation IVF treatment. The main destinations include:

• Kyrgyzstan: Medical costs are relatively low, assisted reproduction is allowed by law, and third-generation technology is mature.
• georgia: Regulations are perfect, the medical system is international, and prices are about 50% of those in the United States.
• USA: The most advanced technology and complete legal protection, but the cost is higher

In surrogate mother-assisted reproduction, the value of PGT-A is particularly significant - because surrogacy itself involves high financial and emotional investment, screening healthy embryos through PGT-A can significantly reduce the risk of transplant failure and miscarriage, and improve the overall success rate.

How should you assess whether you need PGT-A before actually entering treatment?

If you are considering PGT-A technology, it is recommended to follow these steps:

1. Preliminary inspection: Both couples undergo a comprehensive chromosomal examination and fertility assessment
2. genetic counseling: Consult a reproductive genetics specialist to learn whether PGT-A is appropriate for your specific situation
3. Select institution: Choose a reproductive center with formal PGT-A qualifications and laboratories
4. Plan formulation: Discuss with your doctor to develop a personalized ovulation promotion and testing plan
5. Interpretation of results: After the test results come out, discuss the transplant plan with the doctor

Summary: PGT-A is not a master key, but it is often an important tool for improving the quality of decision-making.

PGT-A technology is the core component of the third generation of IVF. It significantly improves the success rate of IVF and reduces the risk of miscarriage by scientifically screening embryos with normal chromosomes. For patients with recurrent miscarriage, advanced age, and repeated transplantation failure, PGT-A is a technical option worth considering.

Of course, PGT-A is not a panacea. Whether to choose PGT-A testing needs to be comprehensively considered based on personal circumstances, financial ability and doctor’s advice. It is recommended that you fully communicate with a professional reproductive medicine team before making a decision to develop a treatment plan that is most suitable for you.